Who
Jakob Dupont
Director
Company insider
Files Form 4 as: Director, Pyxis Oncology; Director, Bolt Biotherapeutics; Director, Apexigen; EVP, Head of R&D, Atara Biotherapeutics; Chief Medical Officer, Gossamer Bio; SVP & Chief Medical Officer, OncoMed Pharmaceuticals.
In numbers
- Trades disclosed
- 123
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $2.3M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 17 Jul 2013
- Last trade
- 20 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 20 Aug 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 20 Aug 2026filed 20 Aug 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code M | $56K35,000 at $1.60 | filing |
| 30 Jun 2026filed 2 Jul 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $107K35,000 at $3.06 | filing |
| 30 Jun 2026filed 2 Jul 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Code M | $56K35,000 at $1.60 | filing |
| 30 Jun 2026filed 2 Jul 2026 | PYXS Pyxis OncologyBiotechnology | SEC FORM 4 Sold | $107K35,000 at $3.06 | filing |
| 10 Jun 2026filed 11 Jun 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 24 Mar 2026filed 25 Mar 2026 | PYXS Pyxis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,867 at $0.00 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,500 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —849 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —849 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,000 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,100 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,100 | filing |
News
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)PYXS · themarketsdaily.com · 8 Oct 2026Contrasting Inovio Pharmaceuticals (NASDAQ:INO) & Pyxis Oncology (NASDAQ:PYXS)PYXS · tickerreport.com · 6 Oct 2026
0 headlines in the last 90 days name Jakob Dupont; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.